NCT02169115View on ClinicalTrials.gov

Urticaria Facticia Treatment With Omalizumab (UFO)

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Symptomatic Dermographism
Interventions
DRUG

Omalizumab

150mg, s.c., every 4 weeks

DRUG

Omalizumab

300mg, s.c., every 4 weeks

DRUG

Placebo

Placebo, s.c., every 4 weeks

Trial Locations (2)

55131

Dermatology University Mainz, Mainz

79104

University Dermatology Freiburg, Freiburg im Breisgau

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Charite University, Berlin, Germany

OTHER